Would you treat beyond 10 years of adjuvant hormonal therapy for premenopausal woman with high risk ER+ HER2 negative breast cancer who remain premenopausal at the end of 10 year adjuvant hormonal therapy?

Community
Company
News
Contact Us
Sign in

Topics: Breast Cancer • Medical Oncology • HR+ • Breast Cancer, Non-metastatic

What factors may influence your decision making?

Related Questions

How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?

Which chemotherapy is preferred between TC and AC-T in a young patient with ER+/PR+/HER2- node negative breast cancer, intermediate grade, with high OncoType score?

Would you offer adjuvant Abemciclib to ER positive HER2 negative with 1 LN positive, Ki-67 >20%, and low Oncotype?

Would you give adjuvant endocrine therapy to a premenopausal woman with early stage node positive breast cancer that was ER negative, PR positive (60%) and HER2 positive?

What adjuvant treatment approach would you choose for a premenopausal woman with lymph node positive poorly differentiated metaplastic breast cancer that is ER low+, PR+, HER2 negative?

Would you recommend adjuvant abemaciclib for ER+ HER2 neg inflammatory breast cancer who do not achieve pCR with neoadjuvant chemotherapy?

How do you approach adjuvant therapy to minimize cardiotoxicity in early stage node negative HER2+ HR+ breast cancer with history of chest wall radiation and previous cardiotoxic agents for Hodgkin Lymphoma?

How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?

Would you offer adjuvant olaparib to a male patient with HR+, HER2- T2N0 breast cancer with a BRCA2 germline mutation following mastectomy who is not a candidate for adjuvant chemotherapy?

In a patient with ER+/HER2+ breast cancer with significant residual disease post neoadjuvant TCHP, is there a role of using CDK4/6i in the adjuvant setting with T-DM1?